

6. (Amended) Structural protein according to [any of Claims 1 to 5] Claim 1, characterized in that it is selected from mutated VP1, mutated VP2 and/or mutated VP3.
7. (Amended) Structural protein according to [any of Claims 1 to 6] Claim 1, characterized in that it is derived from AAV2, AAV3, AAV4, AAV5 and/or AAV6.
8. (Amended) Structural protein according to [any of Claims 1 to 7] Claim 1, characterized in that the mutation(s) is/are point mutation(s), mutation(s) of several amino acids, one or more deletions and/or one or more insertions, or a combination of this mutation.
11. (Amended) Structural protein according to [any of Claims 8 to 10] Claim 8, characterized in that the mutation(s) is/are brought about by one or more insertions at the XhoI cleavage site of the VP1-encoding nucleic acid.
12. (Amended) Structural protein according to [any of Claims 8 to 10] Claim 8, characterized in that the mutation(s) is/are brought about by one or more insertions at the BsrBI cleavage site of the VP1-encoding nucleic acid.
13. (Amended) Structural protein according to [any of Claims 8 to 10] Claim 8, characterized in that the mutation(s) is/are brought about by one or more deletions between the BsrBi/HindII cleavage sites of the VP1-encoding nucleic acid and one or more insertions.

14. (Amended) Structural protein according to [any of Claims 8 to 10] Claim 8, characterized in that one or more insertions in VP3 is/are located before and/or after at least one amino acid in the sequence selected from YKQIS SQSGA, YLTLN NGSQA, YYLSR TNTPS, EEKFF PQSGV, NPVAT, EQYGS, LQRGN RQAAT, NVDFT VDTNG.

17. (Amended) Structural protein according to [any of Claims 1 to 16] Claim 1 in the form of an AAV particle, in particular in the form of an AAV capsid.

18. (Amended) Nucleic acid coding for a structural protein according to [any Claims 1 to 16] Claim 1.

20. (Amended) Process for the preparation of a structural protein according to [any of Claims 1 to 16] Claim 1, characterized in that a cell according to Claim 19 is cultivated and, where appropriate, the expressed structural protein is isolated.

21. (Amended) Medicinal product comprising a structural protein according to [any of Claims 1 to 17] Claim 1, a nucleic acid according to Claim 18 and/or a cell according to Claim 19.

22. (Amended) Diagnostic aid comprising a structural protein according to [any of Claims 1 to 17] Claim 1, a nucleic acid according to Claim 18 and/or a cell according to Claim 19.